Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NextMeds vs Rylo Health

NextMeds
Graded #191

Higher grade

vs+1.5999999999999943
Rylo Health
Graded #236

Lower grade

The verdict

NextMeds takes it — 66.3/100 to 64.7/100, but only just.

NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a… Rylo Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRylo Health +8
56
64
Dose & formulationEven
64
64
Clinical oversightNextMeds +2
77
75
Labs & monitoringNextMeds +8
61
53
FulfillmentNextMeds +1
84
83
Contract termsNextMeds +24
61
37
NextMeds · left barRylo Health · right bar

The numbers

MetricNextMedsRylo Health
WeighScore66.3/10064.7/100
GradeCC
Scorecard rank#191#236
Semaglutide$129/mo (plus a separate fee, compounded)$149/mo (promotional rate, compounded)
Tirzepatide$179/mo (plus a separate fee, compounded)$249/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
NextMeds

Graded #191 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Rylo Health

Graded #236 · C

Strengths

  • Names its dispensing pharmacy in full, with address and phone: VialsRX in Houston, Texas
  • Names its medical group, Lone Star Virtual Health PLLC, and gives a provider contact
  • Standard prices published openly alongside the promotional rate, so the real ongoing cost is visible
  • Cancel in one click from the patient portal, with no contracts and no cancellation fees
  • Peptide line priced openly, including NAD+ and sermorelin

Where it loses points

  • Headline $100 and $160 rates are limited to the first 20 patients; standard rates are $149 and $249
  • No LegitScript certification is claimed or displayed
  • Several peptide products are advertised as coming soon rather than available
  • No published refund policy beyond the no-cancellation-fee statement

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard